Latest Regulation News

Peak Processing has significantly expanded its manufacturing partnership with St. Peter’s Beverages, tripling its SKU production and boosting annual output by up to 700,000 units. This move strengthens its foothold in North America’s cannabis beverage market using proprietary technology.

OzAurum Resources has lodged a key mining proposal for its Mulgabbie North Gold Project, outlining a low-capital, staged heap leach development with strong metallurgical recoveries and an owner-operator model to control costs amid record gold prices.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.

Entropy Neurodynamics reports encouraging early clinical results from the first patient treated with TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, showing improvements across multiple symptom areas.

The ACCC has referred Ampol’s acquisition of EG Australia to a detailed Phase 2 review, citing significant competition concerns in multiple Australian fuel markets. Ampol’s proposed divestments have so far failed to satisfy the regulator.

The ACCC has referred Ampol’s acquisition of EG Australia to a detailed Phase 2 review, citing concerns that the deal could significantly reduce competition in key Australian fuel markets.

Paladin Energy reports a 16% rise in uranium production at Langer Heinrich Mine, with strong sales and a fortified balance sheet positioning the company for growth. Exploration advances in Canada and leadership changes signal a strategic push forward.

Noxopharm has successfully completed the final multiple-dose cohort of its HERACLES trial for SOF-SKN™, reporting no significant safety concerns and paving the way for Phase II-enabling studies.

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

29Metals delivered a robust December quarter at its Golden Grove mine with strong copper and zinc production, while Capricorn Copper remains suspended pending critical regulatory approvals. The company is progressing key growth projects and board changes as it navigates liquidity and operational challenges.

Qoria Limited has reported a record-breaking quarter with annual recurring revenue exceeding US$100 million and a 42% increase in net ARR for Q2 FY2026, reaffirming its strong growth trajectory and FY26 guidance.